• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肥厚型心肌病：综述

Hypertrophic cardiomyopathy: a review.

作者信息

Houston Brian A, Stevens Gerin R

机构信息

Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.

出版信息

Clin Med Insights Cardiol. 2015 Jan 26;8(Suppl 1):53-65. doi: 10.4137/CMC.S15717. eCollection 2014.

DOI:10.4137/CMC.S15717
PMID:25657602
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4309724/
Abstract

Hypertrophic cardiomyopathy (HCM) is a global disease with cases reported in all continents, affecting people of both genders and of various racial and ethnic origins. Widely accepted as a monogenic disease caused by a mutation in 1 of 13 or more sarcomeric genes, HCM can present catastrophically with sudden cardiac death (SCD) or ventricular arrhythmias or insidiously with symptoms of heart failure. Given the velocity of progress in both the fields of heart failure and HCM, we present a review of the approach to patients with HCM, with particular attention to those with HCM and the clinical syndrome of heart failure.

摘要

肥厚型心肌病（HCM）是一种全球性疾病，各大洲均有病例报道，影响着不同性别、各种种族和族裔的人群。HCM被广泛认为是一种单基因疾病，由13个或更多肌节基因中的一个发生突变引起，可突然发生心脏性猝死（SCD）或室性心律失常，也可隐匿地出现心力衰竭症状。鉴于心力衰竭和HCM领域的进展速度，我们对HCM患者的治疗方法进行了综述，尤其关注患有HCM和心力衰竭临床综合征的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4dd/4309724/2f0661082c9a/cmc-suppl.1-2014-053f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4dd/4309724/e167740840a9/cmc-suppl.1-2014-053f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4dd/4309724/bbbe37bdf5e2/cmc-suppl.1-2014-053f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4dd/4309724/19d9263ed784/cmc-suppl.1-2014-053f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4dd/4309724/2f0661082c9a/cmc-suppl.1-2014-053f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4dd/4309724/e167740840a9/cmc-suppl.1-2014-053f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4dd/4309724/bbbe37bdf5e2/cmc-suppl.1-2014-053f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4dd/4309724/19d9263ed784/cmc-suppl.1-2014-053f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4dd/4309724/2f0661082c9a/cmc-suppl.1-2014-053f4.jpg

相似文献

1
Hypertrophic cardiomyopathy: a review.肥厚型心肌病：综述
Clin Med Insights Cardiol. 2015 Jan 26;8(Suppl 1):53-65. doi: 10.4137/CMC.S15717. eCollection 2014.
2
Modes of death and clinical outcomes in adult patients with hypertrophic cardiomyopathy in Thailand.泰国成年肥厚型心肌病患者的死亡模式和临床结局。
BMC Cardiovasc Disord. 2019 Jan 3;19(1):1. doi: 10.1186/s12872-018-0984-0.
3
[Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].[2014年欧洲指南心脏性猝死风险预测模型（HCM Risk-SCD）对中国肥厚型心肌病患者的预测价值]
Zhonghua Xin Xue Guan Bing Za Zhi. 2017 Dec 24;45(12):1033-1038. doi: 10.3760/cma.j.issn.0253-3758.2017.12.006.
4
Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.比较肥厚型心肌病和除颤器患者新的风险预测模型（HCM Risk-SCD）和经典风险因素对猝死的预测价值。
Europace. 2016 May;18(5):773-7. doi: 10.1093/europace/euv079. Epub 2015 Apr 7.
5
Advances in medical treatment of hypertrophic cardiomyopathy.肥厚型心肌病的医学治疗进展
J Cardiol. 2014 Jul;64(1):1-10. doi: 10.1016/j.jjcc.2014.02.022. Epub 2014 Apr 13.
6
Sudden death related cardiomyopathies - Hypertrophic cardiomyopathy.与猝死相关的心肌病 - 肥厚型心肌病。
Prog Cardiovasc Dis. 2019 May-Jun;62(3):212-216. doi: 10.1016/j.pcad.2019.04.001. Epub 2019 Apr 17.
7
Energetic drain driving hypertrophic cardiomyopathy.能量消耗导致肥厚型心肌病。
FEBS Lett. 2019 Jul;593(13):1616-1626. doi: 10.1002/1873-3468.13496. Epub 2019 Jul 4.
8
Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.肥厚型心肌病中与肌节突变相关的临床结局：对 7675 个人的荟萃分析。
Clin Res Cardiol. 2018 Jan;107(1):30-41. doi: 10.1007/s00392-017-1155-5. Epub 2017 Aug 24.
9
Management of hypertrophic cardiomyopathy.肥厚型心肌病的管理。
Ann Glob Health. 2014 Jan-Feb;80(1):35-45. doi: 10.1016/j.aogh.2013.12.004. Epub 2013 Dec 25.
10
Prognostic value of intra-left ventricular electromechanical asynchrony in patients with mild hypertrophic cardiomyopathy compared with power athletes.轻度肥厚型心肌病患者与职业运动员相比，左心室内机电失同步的预后价值。
Br J Sports Med. 2006 Mar;40(3):244-50; discussion 244-50. doi: 10.1136/bjsm.2005.022194.

引用本文的文献

1
Longitudinal Outcomes of Left Ventricular Outflow Tract Obstruction in Aortic Stenosis Versus Hypertrophic Obstructive Cardiomyopathy.主动脉瓣狭窄与肥厚型梗阻性心肌病中左心室流出道梗阻的纵向结局
Medicina (Kaunas). 2025 May 23;61(6):971. doi: 10.3390/medicina61060971.
2
Hypertrophic cardiomyopathy in the trauma patient: A case report and review of the literature.创伤患者的肥厚型心肌病：一例病例报告及文献综述
Trauma Case Rep. 2025 May 26;58:101204. doi: 10.1016/j.tcr.2025.101204. eCollection 2025 Aug.
3
Developmental and Evolutionary Heart Adaptations Through Structure-Function Relationships.

本文引用的文献

1
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).2014年欧洲心脏病学会（ESC）肥厚型心肌病诊断和治疗指南：欧洲心脏病学会（ESC）肥厚型心肌病诊断和治疗工作组
Eur Heart J. 2014 Oct 14;35(39):2733-79. doi: 10.1093/eurheartj/ehu284. Epub 2014 Aug 29.
2
Cardiac involvement in Caucasian patients with pulmonary sarcoidosis.白人肺结节病患者的心脏受累。
Respir Res. 2014 Feb 7;15(1):15. doi: 10.1186/1465-9921-15-15.
3
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
通过结构-功能关系实现的发育和进化心脏适应
J Cardiovasc Dev Dis. 2025 Feb 22;12(3):83. doi: 10.3390/jcdd12030083.
4
Generation of Isogenic iPSC Lines for Studying the Effect of the p.N515del (c.1543_1545delAAC) Variant on MYBPC3 Function and Hypertrophic Cardiomyopathy Pathogenesis.用于研究p.N515del（c.1543_1545delAAC）变异对MYBPC3功能及肥厚型心肌病发病机制影响的同基因诱导多能干细胞系的产生
Int J Mol Sci. 2024 Nov 30;25(23):12900. doi: 10.3390/ijms252312900.
5
Modeling cardiomyocyte signaling and metabolism predicts genotype-to-phenotype mechanisms in hypertrophic cardiomyopathy.建模心肌细胞信号转导和代谢可预测肥厚型心肌病的基因型-表型机制。
Comput Biol Med. 2024 Jun;175:108499. doi: 10.1016/j.compbiomed.2024.108499. Epub 2024 Apr 24.
6
Preoperative evaluation of systolic murmur with point-of-care echocardiography before an elective thoracic surgery - A case report.择期胸外科手术前应用床旁超声心动图对收缩期杂音进行术前评估——病例报告
Anesth Pain Med (Seoul). 2024 Jan;19(1):62-67. doi: 10.17085/apm.23124. Epub 2024 Jan 30.
7
Cardiac Remodeling and Functional Changes in Patients With Hypertrophic Cardiomyopathy: A Longitudinal Observational Study.肥厚型心肌病患者的心脏重塑与功能变化：一项纵向观察研究
Cureus. 2023 Oct 6;15(10):e46610. doi: 10.7759/cureus.46610. eCollection 2023 Oct.
8
A Cardiac Magnetic Resonance Study: Comparison of Biventricular Longitudinal Function in Hypertrophic Cardiomyopathy Patients and Normal Individuals.一项心脏磁共振研究：肥厚型心肌病患者与正常个体双心室纵向功能的比较。
Cureus. 2023 Jan 24;15(1):e34165. doi: 10.7759/cureus.34165. eCollection 2023 Jan.
9
Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy.玛伐卡坦：用于治疗有症状的肥厚性梗阻性心肌病的首款心脏肌球蛋白口服调节剂。
Heart Int. 2022 Oct 5;16(2):91-98. doi: 10.17925/HI.2022.16.2.91. eCollection 2022.
10
Diabetes outcomes in heart failure patients with hypertrophic cardiomyopathy.肥厚型心肌病心力衰竭患者的糖尿病转归
Front Physiol. 2022 Nov 11;13:976315. doi: 10.3389/fphys.2022.976315. eCollection 2022.
射血分数保留心力衰竭中心脏结构和功能：醛固酮拮抗剂治疗保留心脏功能心力衰竭的超声心动图研究的基线发现。
Circ Heart Fail. 2014 Jan;7(1):104-15. doi: 10.1161/CIRCHEARTFAILURE.113.000887. Epub 2013 Nov 18.
4
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).肥厚型心肌病患者心脏性猝死的新型临床风险预测模型（HCM risk-SCD）。
Eur Heart J. 2014 Aug 7;35(30):2010-20. doi: 10.1093/eurheartj/eht439. Epub 2013 Oct 14.
5
Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review.肥厚型心肌病患者的心房颤动和血栓栓塞：系统评价。
Heart. 2014 Mar;100(6):465-72. doi: 10.1136/heartjnl-2013-304276. Epub 2013 Sep 7.
6
Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy.高敏心肌肌钙蛋白 T 在肥厚型心肌病中的意义。
J Am Coll Cardiol. 2013 Oct 1;62(14):1252-1259. doi: 10.1016/j.jacc.2013.03.055. Epub 2013 Apr 23.
7
Hypertrophic cardiomyopathy - Authors' reply.肥厚型心肌病——作者回复。
Lancet. 2013 Apr 27;381(9876):1457-8. doi: 10.1016/S0140-6736(13)60922-8.
8
Effects of ivabradine and ranolazine in patients with microvascular angina pectoris.异搏定和雷诺嗪对微血管性心绞痛患者的影响。
Am J Cardiol. 2013 Jul 1;112(1):8-13. doi: 10.1016/j.amjcard.2013.02.045. Epub 2013 Apr 1.
9
Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.比索洛尔在左心室收缩功能障碍患者中的作用：来自 BEAUTIFUL 和 SHIFT 试验的个体患者数据的汇总分析。
Eur Heart J. 2013 Aug;34(29):2263-70. doi: 10.1093/eurheartj/eht101. Epub 2013 Mar 26.
10
Centrifugal continuous-flow left ventricular assist device in patients with hypertrophic cardiomyopathy: a case series.肥厚型心肌病患者的离心式连续血流左心室辅助装置：病例系列。
ASAIO J. 2013 Mar-Apr;59(2):183-7. doi: 10.1097/MAT.0b013e318286018d.